SLV 339

Drug Profile

SLV 339

Alternative Names: SLV339

Latest Information Update: 13 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novozymes A/S; Solvay
  • Class Pancreatic enzymes
  • Mechanism of Action Lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic disorders

Highest Development Phases

  • Discontinued Pancreatic disorders

Most Recent Events

  • 07 Mar 2009 Discontinued - Phase-II for Pancreatic disorders in European Union (PO)
  • 03 Oct 2006 Phase-I clinical trials in Pancreatic disorders in European Union (unspecified route)
  • 03 Oct 2006 SLV 339 received Orphan Drug status for Pancreatic disorders in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top